胸腺肽α1在鼻咽癌治疗中的应用研究

Exploratory development of thymosin alpha 1 for nasopharyngeal carcinoma therapy

目的:评价胸腺肽α1(Tα1)在鼻咽癌放化疗中的作用.方法:选择新疆医科大学附属肿瘤医院2007-03/2008-12病理确诊的初治鼻咽癌患者42例,随机分成调强放化疗联合胸腺肽α1组(简称Tα1组)与调强放化疗组(简称对照组),用ELISPOT方法检测放化疗前和放化疗后3个月患者外周血中分泌IFN-γ的特异性细胞毒性T细胞(CTL)的频数变化,比较Tα1组与对照组近期疗效、急性皮肤粘膜反应及骨髓抑制的差异,分析联合应用免疫增强剂后免疫功能的变化.结果:Tα1组和对照组治疗前后外周血中分泌IFN-γ的CTL细胞频数的差异均有统计学意义(P<0.05);两组之间CTL细胞频数差异在治疗前后均无统计学意义,但Tα1组患者的CTL细胞增加数目明显高于对照组.两组皮肤、粘膜反应差异有统计学意义,骨髓抑制差异无统计学意义.结论:鼻咽癌患者调强放化疗联合Tα1可能有助于提高患者的特异性细胞免疫能力,减轻放疗引起的急性皮肤、粘膜反应.

AIM：To evaluate the effect of thymosin alpha 1（Tα1）for nasopharyngeal carcinoma therapy.METHODS：A total of 42 nasopharyngeal carcinoma patients who visited The Affiliated Tumor Hospital of Xinjiang Medical University during the time from 2007-03 to 2008-12 and underwent initial treatment after definite diagnose by patholog were included in the study,randomly divided into chemoradiotherapy with Tα1 group（Tα1 group）and chemoradiotherapy group（Control group）.To detect the number of specific cytotoxicity t lymphocyte（CTL）secreting IFN-γ in peripheral blood by ELISPOT methods before chemoradiotherapy and after chemoradiotherapy for 3 months,to compare the short-time effect,acute reaction of skin and mucosa,myelosuppression between the 2 groups,and to analyze the variation in immunological function after using immunopotentiator.RESULTS：The number of specific CTL secreting IFN-γ existed significant differences（P〈0.05）before chemoradiotherapy and after chemoradiotherapy for 3 months in the .2 groups;There was no statistical significance between the 2 groups in the number of specific CTL before chemoradiotherapy and after chemoradiotherapy for 3 months,but the number of specific CTL in Tα1 group were more than Control group.Acute reaction of skin and mucosa existed significant differences between the two groups,but reversed in myelosuppression.CONCLUSION：Chemoradiotherapy combind with Tα1 may help improve the specific cell immunocompetence and reduce the acute reaction of skin and mucosa for nasopharyngeal carcinoma.